Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 75 clinical trials
Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology( CHAVI-RO )

In this phase, our study will include data sets of five types of cancers namely, breast, head and neck, brain, cervix and lung cancer. We propose to demonstrate the application of this data set in cancer research. We will work on serial PET-CT based radiomics of breast and cervix cancer …

  • 0 views
  • 19 Feb, 2024
Early Cancer Detection Test - Lung Cancer China

Lung cancer is the most common cancer in China from both incidence and mortality rate point of view, with significantly lower 5-year survival rate than average.

low-dose chest computed tomography
early diagnosis
lung cancer
cancer screening
cancer
  • 0 views
  • 19 Feb, 2024
Manchester Lung Health Study

The Manchester Lung Health Study (qUEST) will assess the uptake of a community-based lung cancer screening service and its impact across a deprived area of North and East Manchester, which has high rates of lung cancer. One measure will be to compare the number and stage of lung cancers detected …

low-dose chest computed tomography
ct scan
ct scan chest
cancer screening
chest ct
  • 0 views
  • 19 Feb, 2024
Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020

Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade. Primary endpoint: Estimate 1-year- and 5-year-mortality rates in patients with PLC. Secondary …

liquid biopsy
lung cancer
cancer
  • 0 views
  • 19 Feb, 2024
ESCAP-2020-CPHG: Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort Patients

The prognosis for primary lung cancer (PLC) is very limited. In France, patients diagnosed for PLC in 2010 and followed in Respiratory Medicine or Oncology department of a General Hospital Centre had a 5-year survival rate of 12.7% (vs 10% in 2000).

immunohistochemistry
lung cancer
cancer
liquid biopsy
  • 0 views
  • 19 Feb, 2024
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection

The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.

covid-19
lung cancer
blood test
elisa
cancer
  • 0 views
  • 19 Feb, 2024
A Prospective Cohort of Pulmonary Ground Glass Nodules Patients With Family History.

The aim of the present prospective cohort study (GGN-F) is to study the family aggregation of pulmonary ground glass nodules via the questionnaire survey and to investigate the underlying genetic mechanism via the biobank.

lung cancer
cancer
  • 0 views
  • 19 Feb, 2024
Clinical Study on Raman Spectra of Blood Saliva and Urine in Patients With Cancer Treated by Modern Therapy

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral.

targeted therapy
cancer
  • 0 views
  • 19 Feb, 2024
Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

To determine the optimal EGFR TKIs treatment strategies for lung adenocarcinoma harboring EGFR exon 19 deletion variants

  • 0 views
  • 19 Feb, 2024
Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC. The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.

carcinoma in situ
melanoma
carcinoma of the cervix
immunomodulators
non-melanoma skin cancer
  • 0 views
  • 19 Feb, 2024